CytomX Therapeutics, Inc.

172 articles with CytomX Therapeutics, Inc.

• CytomX Therapeutics Announces New Employment Inducement Grants - June 16, 2022

  6/16/2022

  CytomX Therapeutics, Inc. announced that on June 15, 2022, the Company granted two new employees options to purchase a total of 109,000 shares of the Company’s common stock at an exercise price per share equal to $1.72, which was the closing trading price on June 15, 2022, the date of the grant.

• CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

  6/1/2022

  CytomX Therapeutics, Inc. announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET.

• 

  Clinical Catch-Up: 3's the Charm for Pfizer-BioNTech Vaccine in Kids & More

  5/30/2022

  A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.

• CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic -

  5/26/2022

  CytomX Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 ( NCT05387265 ).

• CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

  5/5/2022

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported first quarter 2022 financial results and provided a business update.

• CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

  4/28/2022

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of U.S. markets.

• CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

  4/14/2022

  CytomX Therapeutics, Inc. announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.

• CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

  3/17/2022

  CytomX Therapeutics, Inc. today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine program will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

• CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update

  3/1/2022

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported fourth quarter and full year 2021 financial results, and provided a business update.

• CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

  2/28/2022

  CytomX Therapeutics, Inc. today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virtual panel discussion at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

• CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

  2/22/2022

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022, after the close of U.S. markets.

• CytomX Therapeutics Announces New Employment Inducement Grants - Feb 16, 2022

  2/16/2022

  CytomX Therapeutics, Inc. announced that on February 16, 2022, the Company granted nine new employees options to purchase a total of 189,400 shares of the Company’s common stock at an exercise price per share equal to $4.08, which was the closing trading price on February 15, 2022, the date of the grant.

• 

  BioSpace Movers & Shakers, Feb. 11

  2/11/2022

  Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

• CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

  2/7/2022

  CytomX Therapeutics, Inc. today announced the promotion of Amy C. Peterson, M.D., to the position of president and chief operating officer, effective immediately.

• CytomX Therapeutics Announces New Employment Inducement Grants - Jan 20, 2022

  1/20/2022

  CytomX Therapeutics, Inc., a leader in the field of conditionally activated therapeutics, announced that on January 18, 2022, the Company granted four new employees options to purchase a total of 127,000 shares of the Company’s common stock at an exercise price per share equal to $3.83, which was the closing trading price on January 18, 2022, the date of the grant.

• CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

  1/19/2022

  CytomX Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for CX-904, an EGFRxCD3 T-cell-engaging bispecific antibody being co-developed by CytomX and Amgen.

• CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th at 3:00 p.m. ET.

• CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71

  12/20/2021

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), today announced preliminary Phase 2 results in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC), who were treated with CX-2029 – a CD71-directed conditionally activated antibody-drug conjugate (ADC) being co-developed by CytomX and AbbVie.

• CytomX Therapeutics to Present at Upcoming November Investor Conferences

  11/11/2021

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in virtual fireside chats at the following investor conferences in November.

• CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

  11/4/2021

  CytomX Therapeutics, Inc. today reported third quarter 2021 financial results and provided a business update.